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The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces
Parkinson’s disease-like symptoms following administration to mice, monkeys, and
humans. A common view is that MPTP is metabolized to 1-methyl-4-phenylpyridinium
ion (MPP+ ) to induce its neurodegenerative effects on dopaminergic neurons in the
substantia nigra (SN). Moreover, the hippocampus contains dopaminergic fibers, which
are projecting from the ventral tegmental area, SN and pars compacta and contain the
whole machinery required for dopamine synthesis making them sensitive to MPTP and
MPP+. Here, we present data showing that acute bath-application of MPP+ elicited
a dose-dependent facilitation followed by a depression of synaptic transmission of
hippocampal Schaffer collaterals-CA1 synapses in mice. The effects of MPP+ were
not mediated by D1/D5- and D2-like receptor activation. Inhibition of the dopamine
transporters did not prevent but increased the depression of excitatory post-synaptic
field potentials. In the search for a possible mechanism, we observed that MPP+
reduced the appearance of polyspikes in population spikes recorded in str. pyramidale
and increased the frequency of miniature inhibitory post-synaptic currents. The acute
effect of MPP+ on synaptic transmission was attenuated by co-application of a
GABAA receptor antagonist. Taking these data together, we suggest that MPP+ affects
hippocampal synaptic transmission by enhancing some aspects of the hippocampal
GABAergic system.
Keywords: Parkinson’s disease, dopaminergic system, extrasynaptic GABAergic receptors, synaptic
transmission, tonic inhibition, limbic system
Introduction
Parkinson’s disease (PD) is characterized by movement-related motor dysfunctions (e.g.,
tremor, akinesia, and rigidity; Rodriguez-Oroz et al., 2009). In addition, some patients with
PD show an impairment of cognitive functions (Whittington et al., 2006; Lee et al., 2010;
Weiermann et al., 2010) and have mild cognitive impairment (MCI; Fernandez et al., 2005;
Goldman and Litvan, 2011) or dementia (Emre et al., 2007; Aarsland and Kurz, 2010)
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including impairments of declarative memory (Bondi and
Kaszniak, 1991).
Whereas the genesis of sporadic PD and PD with dementia is
still under debate, a correlation between PD cases and the extent
of the use of herbicides and pesticides has been described (Liou
et al., 1997; Stephenson, 2000; Sun et al., 2007; Tanner et al.,
2011). In animal models, the herbicide paraquat causes death of
dopaminergic neurons within the substantia nigra (SN), ventral
tegmental area (VTA) and as well as the degeneration of the
dopaminergic ﬁbers within the striatum (Ren et al., 2009) – a
hallmark of PD onset.
Compounds with a structure similar to the herbicide paraquat,
have been reported to induce severe motor dysfunction that
closely resembles an advanced stage of PD (Przedborski et al.,
2001; Dauer and Przedborski, 2003). One such compound is
the neurotoxin 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine
(MPTP). Systemic administration of MPTP in primates and
mice causes motor dysfunctions, as well as cognitive deﬁcits that
correlate with depletion of dopamine in the midbrain (Bove et al.,
2005) and hippocampus (Zhu et al., 2011) within several days
after its administration. In addition, dopaminergic denervation
was shown to potentiate GABAergic inhibition in the mouse
neostriatum (Schlosser et al., 1996). It is a common view that
MPTP has to be metabolized to 1-methyl-4-phenylpyridinium
ion (MPP+) via monoamine oxidase in glia cells and that
MPP+ in turn is transported into dopaminergic neurons via
the dopamine transporter (DAT). Since the expression of
monoamine oxidase in glia cells is not restricted to the SN or VTA
a metabolism of MPTP can take place in other brain areas such as
the hippocampus.
Cognitive abilities, such as formation of declarative memory
rely partially on the hippocampus (Manns and Eichenbaum,
2006; Morris, 2006) and are known to be modulated by
the dopaminergic system. Interference with hippocampal
neurotransmission (Bliss and Collingridge, 1993; Morris, 2006)
could therefore represent a putative mechanism for altering
memory performance in PD patients.
In addition, it is known that a major mesolimbic projection
toward the CA1 area of the hippocampus contains dopaminergic
ﬁbers originating from the VTA, SN, and pars compacta
(Gasbarri et al., 1994, 1997), and that these hippocampal
dopaminergic ﬁbers contain the whole machinery required
for dopamine synthesis and recycling, including DAT (Lisman
and Grace, 2005). However, the putative eﬀects of MPP+
on their aﬀerents and subsequently on hippocampal synaptic
transmission are not well understood (Galvan et al., 1987). We
focused on the acute eﬀects of MPP+ on hippocampal excitatory
synaptic transmission, to diﬀerentiate from the chronic eﬀects of
MPTP and MPP+.
Here, we looked into the eﬀects of MPP+ on synaptic
transmission at hippocampal Schaﬀer collateral (SC)-CA1
synapses using recordings of ﬁeld excitatory post-synaptic
potentials (fEPSPs), polyspikes and miniature inhibitory post-
synaptic currents (mIPSCs). The data suggest that MPP+ dose-
dependently aﬀects synaptic transmission in acute hippocampal
slices of C57BL/6 mice via modulation of some aspects of the
GABAergic system.
Materials and Methods
Animals
Young adult male C57BL/6 mice (8 weeks) were supplied
from the animal center of the Chinese Academy of Sciences
(CAS, Shanghai, China) and maintained in accordance with
the established standards of animal care and procedures of the
Institutes of Brain Science and State Key Laboratory of Medical
Neurobiology of Fudan University, Shanghai, China. Eﬀorts were
made to minimize the number of animals used. Animals had free
access to food and water.
In addition, all studies and individual protocols were
conducted in accordance with the GSK Policy on the Care,
Welfare and Treatment of Laboratory Animals and were
reviewed by the Institutional Animal Care and Use Committee
either at GSK or by the ethical review process at the Institutes of
Brain Science and State Key Laboratory of Medical Neurobiology
of Fudan University, Shanghai, China.
Electrophysiology
Hippocampal Slice Preparation
Hippocampal slices were prepared as described previously
(Leutgeb et al., 2003; Cai et al., 2010; Zhu et al., 2011, 2012).
Brieﬂy, after anesthesia with isoﬂurane, brains were removed
and immersed in pre-carbogenated (95% O2/5% CO2) ice-cold
ACSF (composition in mM: 119 NaCl, 2.5 KCl, 2.5 CaCl2·2H2O,
1.3 MgCl2·7H2O, 1 NaH2PO4, 11 glucose, 26.2 NaHCO3, pH
7.4). A piece of the entorhinal cortex was sliced oﬀ and the
two hemispheres glued with the midline surface on the slicing
platform of the sectioning system. Transverse hippocampal slices
(350 µm) were cut and maintained in a submerged-incubation
chamber for at least 1 h at room temperature (25◦C) and then
transferred to a submerged type recording chamber system and
further incubated for at least 30 min at 32◦C under constant
perfusion (4 ml/min) with carbogenated ACSF.
Field Potential Recording
Field excitatory post-synaptic potentials were recorded in the
stratum radiatum (str. rad.) of the hippocampal CA1 area via
borosilicate micropipettes ﬁlled with ACSF. Bipolar stimulation
electrodes were used to stimulate SC ﬁbers within the str. rad.
every minute. Recorded ﬁeld potentials were ampliﬁed by StAmp
(Scientiﬁca, UK) and then digitized at a sample frequency of
10 kHz and ﬁltered (1 kHz low-pass, 1 Hz high-pass). The
stimulation strength was adjusted to ∼40–50% of the maximum
fEPSP-slope value. Paired-pulse facilitation (PPF) of fEPSPs was
recorded at a 50 ms inter-stimuli interval.
Polyspike Recording
Repeated aﬀerent stimulation of SCs for 30 s at 1 Hz evokes
multiple population spikes (PSs) in the CA1 region due to
the reduction of GABAergic transmission (Luthi et al., 1997;
Saghatelyan et al., 2004). SCs were stimulated with a bipolar
platinum electrode placed in the str. rad. at a position ∼400 µm
from the recording electrode. ACSF-ﬁlled glass pipettes had
a resistance of about 2 MOhm and were placed in the str.
pyramidale. Themono-phasic stimulation pulse width was 0.2ms
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and the stimulation strength was adjusted to evoke a PS of
maximal amplitude. The CA3 region was sliced oﬀ from the
CA1 region to avoid bursts originating from recurrent excitation
of the CA3 region. The areas of the ﬁrst and following PSs
were measured and compared to the area of the ﬁrst spike.
To this end a line was drawn manually from the positive
peak after the ﬁrst spike to the recovery of the last detectable
negative deﬂection. In Figures 4C,D such lines are indicated
with dotted lines. The upper limit of the ﬁrst spike was deﬁned
from the onset of the negative deﬂection to the ﬁrst positive
maximum.
Whole-Cell Voltage-Clamp Recording
Miniature inhibitory post-synaptic currents of CA1 neurons
were recorded using 3–5 MOhm pipettes ﬁlled with a solution
containing (in mM): Cs-gluconate 117, NaCl 2.8, EGTA-acid 0.4,
HEPES 20, tetraethylammonium chloride 5, ATPMg 2, GTP Na2
0.2, glucose 10, pH 7.25. Tetrodotoxin (TTX; 1 µM) and CNQX
(25 µM) were added to the ACSF to prevent action potential
driven transmitter release and excitatory transmission. mIPSCs
were recorded by a Multiclamp 700B ampliﬁer, digitalized with
Digidata 1440 and acquired by Clampex 10.2 software (Molecular
Devices, Silicon Valley, CA, USA). Membrane potentials were
held at −70 mV and currents were processed through 1 kHz
low-pass and 0.1 Hz high-pass ﬁlters. mIPSC amplitude and
frequency were analyzed using MiniAnalysis 6 (Synaptosoft Inc.,
Fort Lee, NJ, USA). mIPSCs were collected for intervals of three
min before (baseline), and 10 and 30 min after MPP+ or vehicle
application. Statistical comparison of data was performed using
the Student’s or non-parametric tests for unpaired or paired
samples.
Statistical Analysis
Maximal fEPSP-slopes were determined and expressed in
percentages as mean ± standard error of mean (SEM). The
values for diﬀerent experimental conditions were compared
using t-test or non-parametric tests (Mann–Whitney U-test or
Wilcoxon signed-ranks test; SPSS). A p < 0.05 was considered
to indicate a statistically signiﬁcant diﬀerence between two
groups. Brackets are used to indicate the range of signiﬁcant
diﬀerence between groups for the corresponding time points
(p < 0.05). Drug experiments were interleaved with drug-free
controls.
Results
MPP+ Modulates Excitatory Synaptic
Transmission of Schaffer Collateral-CA1
Synapses
To examine the eﬀects of MPP+ on hippocampal synaptic
transmission in acute hippocampal slices from C57BL/6 mice,
fEPSPs were recorded in the str. rad. of the CA1 region.
We observed that in response to the MPP+ application an
enhancement of fEPSPs was induced within 15 min that was
followed by a depression of fEPSPs. We found that 10 µM
MPP+ decreased the fEPSP slope within 90 min of application to
78.6 ± 4.7%, 30 µM to 69.9 ± 8.3%, and 100 µM to 22.0 ± 1.5%.
The averaged fEPSP slope 90 min after vehicle bath-application
was 102.3 ± 4.6% (N = 2, n = 4; Figure 1A).
We were interested to learn whether the acute MPP+ eﬀect is
lasting after wash out.
The degree of recovery after MPP+ application was measured
20 min after MPP+ wash-out (110th min). The fEPSP slope
values 20 min after MPP+ wash-out were compared to 90th
min values (Figure 1B). fEPSPs recovered within 20 min of the
wash-out and the fEPSP slope increased from 94.6 ± 2.6% to
119.5 ± 6.1% and from 70.7 ± 4.6% to 97.7 ± 8.1% at the
110th min in the 10 and 30 µM MPP+ (n = 4) experiments,
respectively. The fEPSP recovery after the wash-out of MPP+ was
signiﬁcantly diﬀerent for the 10 and 30 µM MPP+ experiments,
however, a restoration of fEPSP was not observed after 100 µM
MPP+ (Figure 1B). These results imply a dose-dependent and
partially reversible acute modulation of hippocampal synaptic
transmission by MPP+.
The PPF of 30 and 100 µM MPP+ groups decreased to
85.3± 4.4% and 91.4± 2.6%, and was signiﬁcantly diﬀerent from
the PPF ratio 99.2 ± 3.2% of the control group. The PPF was
reduced signiﬁcantly, however, to a similar degree at all tested
MPP+ concentration 30 min after its application (Figure 1C).
This shows that the PPF is highly sensitive toward MPP+
and already saturated at 10 µM. Whether the MPP+ eﬀect
on PPF is linked to a reduction of presynaptic vesicle release
probability of the available vesicle storage pool as shown for
MPTP (Serulle et al., 2007) or to a disturbed interaction of parkin
and endocytosis regulating proteins (Trempe et al., 2009) remains
to be studied.
Inhibition of Monoamine Transporters does not
Alter MPP+ Mediated fEPSP Depression
Toxicological research has shown that MPP+ enters
dopaminergic aﬀerents through the DAT (Clarke and Reuben,
1995; Kitayama et al., 1998; Storch et al., 2004). In addition,
monoamine transporters for norepinephrine and serotonin
also have aﬃnities toward MPP+ and are responsible to a
certain degree for its uptake (Piﬂ et al., 1996). There are several
publications showing that in the hippocampus, such monoamine
transporters are expressed in dopaminergic, norepinephrinergic,
and serotoninergic aﬀerents (Borgkvist et al., 2012; Tang et al.,
2014). In order to examine whether the observed MPP+
eﬀect on fEPSP depends on these transporters, we applied the
non-selective monoamine transporter inhibitor indatraline, or
co-applied this inhibitor with the norepinephrine/DAT inhibitor
nomifensine or together with the serotonin transporter inhibitor
ﬂuoxetine. After pretreatment with the inhibitors for 30 min to
suppress the activity of monoamine transporters in hippocampal
slices, we observed that the MPP+ mediated depression of fEPSP
became enhanced in comparison to control measurements.
In particular, co-application of 10 µM indatraline (N = 3,
n = 9) and MPP+ decreased fEPSPs to 39.7 ± 11.8% within
the 100 min of recording (Figure 2A). In comparison to MPP+
alone (61.4± 4.8%, N = 3, n = 8) this reduction was signiﬁcantly
diﬀerent. A similar eﬀect on the MPP+ mediated fEPSP decrease
was seen after co-application with 10 µM nomifensine and
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FIGURE 1 | Acute MPP+ application alters excitatory synaptic
transmission of Schaffer collateral-CA1 synapses. (A) MPP+ modulates
hippocampal synaptic transmission in a concentration-dependent manner. In
the CA1 region, application of 10, 30, and 100 µM MPP+ caused a
concentration dependent fEPSP enhancement followed by a fEPSP depression.
The MPP+ application started immediately after the sixth baseline recording
(−5 min), however, the values, taken 5 min later, have been indicated in the
figure as the time point 0, the onset of the MPP+ effect. Inserts show sample
traces of fEPSPs corresponding to the time points indicated with 1, 2, and 3 in
the graphs below. (B) fEPSPs recovered partially within 20 min after MPP+
wash-out. The white bars show the averaged fEPSP slope values after 90 min
of MPP+ bath-application and the gray bars the values 20 min after MPP+
wash-out. 10 and 30 µM MPP+ bath-application caused a depression of
fEPSPs, which recovered within 20 min after MPP+ wash-out in comparison to
the fEPSP slope values following 90 min of MPP application. (C) Paired-pulse
facilitation (PPF: 50 ms) of fEPSPs is reduced by MPP+ within 30 min of MPP+
application. The PPF was reduced significantly, however, to a similar degree at
all tested MPP+ concentrations. Corresponding fEPSP traces are depicted
above diagrams. Horizontal scale bars indicate 10 ms and the vertical one
0.5 mV. The black horizontal bar shows the MPP+ application period. Small
numbers inside the bars indicate the time point of the measurement. Brackets
enclose all time points where the group values are significant different from each
other (∗p < 0.05). The compared groups are indicated with their corresponding
symbols used in the line graph.
10 µMﬂuoxetine (N = 3, n = 8) that caused a signiﬁcantly larger
MPP+ mediated fEPSP depression within 100 min (31.6 ± 9.6%;
Figure 2B).
Our results indicated that the suppression of monoamine
transporters does not attenuate the MPP+ eﬀect on hippocampal
synaptic transmission, but facilitates the MPP+ mediated fEPSP
depression. This observation might indicate that a reuptake
of MPP+ by monoamine aﬀerents is not required for the
MPP+ mediated fEPSP depression. We could speculate here that
inhibition of monoamine transporters might enhance the MPP+
availability in the extracellular space.
MPP+ Mediated fEPSP Depression does not
Depend on Dopamine Receptors
It has been shown that MPP+ administration in the striatum
leads to an increase of extracellular dopamine concentration
(Obata, 2002; Faro et al., 2009). We could not ﬁnd data in
the literature regarding MPP+ induced dopamine release from
dopaminergic aﬀerents in the hippocampus; however, it might
take place based on the similarities of their dopaminergic
pathway. Thus, we further investigated whether MPP+ aﬀects
hippocampal synaptic transmission by activation of dopamine
receptors.
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FIGURE 2 | Effects of monoamine transporter antagonists on MPP+
mediated fEPSP depression. (A) Application of the dopamine transporter
(DAT) antagonist indatraline (Inda; 10 µM, light gray filled triangle) 30 min before
MPP+ application up to the end of recording did not prevent the enhancement
of fEPSPs, but increased the fEPSP depression. (B) Co-application of
nomifensine (Nomi) and fluoxetine (Fluo, light gray triangle) 30 min before MPP+
application up to the end of recording facilitated significantly MPP+ mediated
fEPSP depression in comparison to MPP+ application alone (dark gray circles).
Co-application of Nomi and Fluo (empty diamonds) did not alter fEPSPs in
baseline stability measurements. Baseline sample fEPSP traces and traces for
the 15-, and 90-min time points are shown above the graphs. The horizontal
scale bar indicates 10 ms and the vertical one 0.5 mV. The application period of
MPP+ or monoamine transporter antagonists is shown with black or gray
horizontal lines, respectively. Brackets enclose all time points where the group
values are significant different from each other (∗p < 0.05). The compared
groups are indicated with their corresponding symbols above the brackets.
Application of the dopamine D2-like receptor antagonist
haloperidol attenuated the MPP+ induced fEPSP-slope
enhancement within the ﬁrst 15∼20 min to 103.3 ± 3.1%
(N = 5, n = 7) compared with the 115.6 ± 2.8% in the MPP+
alone group (N = 3, n = 8). However, haloperidol did not
alter the MPP+ induced fEPSP depression within 120 min of
recording (Figures 3A,B).
The dopamine D2-like receptor antagonist sulpiride 40 µM
(N = 2, n = 7) did not aﬀect the 30 µM MPP+ induced
enhancement of synaptic transmission, and did not modulate
the corresponding fEPSP depression (20 min: 113.8 ± 9.3%;
Figure 3C).
At a concentration of 100 µM MPP+, 12 µM haloperidol co-
applied with dopamine D1-like receptor antagonist SCH23390
10 µM (N = 2, n = 4) did not antagonize the enhancement of
fEPSPs and did not alter the MPP+ mediated fEPSP depression
(Figure 3D).
Attenuation of Polyspike Appearance Indicates
Modulation of the Inhibitory System by MPP+
Previous experiments suggested that the MPP+ mediated fEPSP
modulation does not depend on monoamine transporters and
D1/D5- and D2-like dopamine receptors. Since it is known
that alteration of the GABAergic system can inﬂuence the
eﬃciency of synaptic transmission (Ault and Nadler, 1982; Davies
and Collingridge, 1996), we conducted experiments to study
the involvement of this inhibitory system in MPP+ mediated
alteration of excitatory synaptic transmission.
A reduction of the strength of GABAergic inhibition can be
evoked by repetitive low-frequency stimulations, which cause
the appearance of additional PSs, referred to as “polyspikes”
(Saghatelyan et al., 2004). The eﬀect of MPP+ on the appearance
of polyspikes was analyzed by measuring the area of the ﬁrst and
second PS followed by normalization of the polyspike area to
the area of the ﬁrst spike (Figures 4A,C,D). We observed that
after 30 min of 10 or 100 µMMPP+ application, the normalized
area of the second spike was 57.5 ± 16.5% (N = 4, n = 8) and
50.6 ± 20.4% (N = 3, n = 4). The value for the normalized
area before MPP+ application was 178.1 ± 14.4% (N = 5,
n = 9; Figures 4B,D). As shown in Figures 4A,B these values
are signiﬁcantly diﬀerent and demonstrate that MPP+ increases
the strength of the GABAergic system.
MPP+ Affects the Frequency of Miniature
Inhibitory Post-synaptic Currents (mIPSCs)
The previous experiments gave some hints that MPP+ might
interfere with synaptic transmission by modulation of an
inhibitory system. To further expand this hypothesis, we
analyzed the eﬀect of MPP+ on mIPSCs using whole-cell
voltage clamp of CA1 neurons. We found that 100 µM MPP+
increased the number of mIPSC events to a signiﬁcant extent
in comparison to MPP+ free experiments (Figures 5A,B). The
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FIGURE 3 | Role of the dopaminergic system in MPP+ mediated fEPSP
facilitation and depression. (A) Application of the D2-like dopamine receptor
antagonist haloperidol (Halo; 12 µM, light gray triangles) 30 min before MPP+
application up to the end of recording significantly reduced fEPSP-slope
facilitation within the first 30 min of MPP+ application, but did not alter fEPSP
depression induced by MPP+ (30 µM, gray circles). Corresponding sample
traces are shown above the graphs for time points indicated by black (baseline),
dark gray (10 min) and light gray (120 min) lines. (B) Bar graph emphasizes the
presentation of the Halo effect on 30 µM MPP+-mediated fEPSP-slope
facilitation for the time point 30 min. (C) Application of the D2 receptor
antagonist sulpiride (40 µM, light gray triangles) did not alter MPP+-mediated
fEPSP alterations (dark gray circles). (D) Co-application of Halo and D1/D5-like
dopamine receptor antagonists (light gray triangle) did not affect the 100 µM
MPP+-mediated fEPSP-facilitation and depression (black circles). Sample
traces are shown above both graphs for each time point as indicated. The
horizontal scale bar represents 10 ms and the vertical one 0.5 mV. The
application period of MPP+ or other compounds is shown with black or gray
horizontal lines, respectively. Brackets and asterisks indicate the significant
difference between groups (∗p < 0.05). The compared groups are indicated
with their corresponding symbols used in the line graph.
mIPSC frequency increased to 171.6 ± 24.4% of baseline after
10 min MPP+ treatment, which was signiﬁcantly higher than
the 87.8 ± 11.2% of the control experiments (Figures 5D,F).
In contrast, the amplitude of the mIPSCs was not signiﬁcantly
altered (Figures 5C,E). More speciﬁcally, after 10 min of
100 µM MPP+ (N = 6, n = 6) the mIPSC amplitude
increased to 150.0 ± 37.1% of baseline values, whereas in
control measurements the amplitude was 86.9 ± 17.5% (N = 2,
n = 4). 30 min after 100 µM MPP+ the mIPSC amplitude
increased further to 180.9 ± 45.6% of baseline values (N = 4,
n = 6), whereas in control measurements the amplitude was
127.3± 21.4% (Figure 5E). The frequency after 100µMMPP+ at
30 min was 255.6± 34.7% compared to 138.7± 36.0% in control
group (Figure 5F).
The holding current (HC) at 10 and 30 min was normalized
to the baseline holding (B) current [(HCt-HCB)/HCB∗100%].
MPP+ increased the HC by about 100% within 10 and 30 min.
This increase was signiﬁcantly diﬀerent to the 10 min value of the
control group (N = 2, n= 4). The HC after 10 and 30 min MPP+
application was also signiﬁcantly diﬀerent to their baseline values
(Figure 5G).
Role of GABAergic Receptors in MPP+-Induced
Depression of Synaptic Transmission
To clarify if the MPP+ induced fEPSP depression was mediated
by activation of GABAergic receptors; we co-applied MPP+
together with a GABAA or GABAB receptor antagonist. We
observed that the GABAA receptor antagonist bicuculline
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FIGURE 4 | Reduced polyspike appearance after MPP+. (A) The time
course of low-frequency induced polyspike appearance measured every
10 min in experiments with MPP+ (10 µM MPP+: gray filled circles; 100 µM
MPP+: black filled circles) and without MPP+ (empty diamonds) is shown.
∗∗∗p < 0.001 between control and 100 µM MPP+. (B) The bar graph
illustrates averaged values of the normalized polyspike area 30 min after start
of recording for the control and MPP+ experiments. ∗∗∗p < 0.001 between
control and MPP+ experiments. Sample traces of the first (black line) and
the last (gray line) population spike of the 30 stimuli, 1 Hz train are
presented for (C) control and (D) MPP+ experiments. Dashed gray lines
indicate extrapolated baselines utilized for polyspike area calculation. Scale
bars: 1 mV and 10 ms.
(10 µM; N = 5, n = 12) signiﬁcantly attenuated the
decrease of the fEPSP slope value within 45 min of MPP+
(Figure 6A). The normalized fEPSP slope value at the 90th
min was, with 64.6 ± 9.8%, signiﬁcantly larger than the
19.6 ± 2.0% of the 100 µM MPP+ group (N = 4, n = 8).
However, the GABAA receptor antagonist did not prevent
the initial fEPSP enhancement by MPP+. Application of the
GABAB receptor speciﬁc antagonist CGP52432 (CGP) did
not prevent fEPSP depression, but ampliﬁed and prolonged
the initial fEPSP enhancement induced by 30 µM MPP+
(Figure 6B).
Thus, we suggest that bicuculline-sensitive GABAA receptors
play a key role in the MPP+ induced fEPSP depression and that
an inhibitory eﬀect of MPP+ on GABAB receptors might be the
cause for the initial fEPSP enhancement.
Discussion
The initial design of the experiments was based on the
assumption that MPP+ might aﬀect hippocampal synaptic
transmission of the dopaminergic system by modulation of
dopamine release from nerve terminals and/or eﬀects at
dopamine receptors. This assumption was based on data showing
that MPP+ is actively transported into dopaminergic neurons of
the SN by the dopamine transporter complex (DAT) reducing
ATP production and loss of mitochondrial membrane potential
leading to the damage of the mitochondrial respiratory chain
complex. Since hippocampal dopaminergic aﬀerents also contain
DAT (Lisman and Grace, 2005) it was reasonable to presume
that MPP+ induces axonopathy of hippocampal dopaminergic
aﬀerents by entering the ﬁbers through DAT. However, in
our experiments, none of the tested monoamine transporter
inhibitors attenuated the MPP+ eﬀect on fEPSPs, but on the
contrary, facilitated MPP+ induced fEPSP depression. Since
application of the inhibitors alone did not aﬀect fEPSPs in a
similar manner to MPP+, we can exclude interference of MPP+
with monoamine transporters as a cause of MPP+ induced fEPSP
depression.
MPP+ is known to induce dopamine release in the striatum by
modulation of voltage-dependent calcium channels and reversal
of DAT in striatal neurons (Inazu et al., 2001). In addition,
in other brain regions with dopaminergic neurons increases
of extracellular dopamine in response to the acute MPP+
application have been shown (Faro et al., 2009). As mentioned
before, hippocampal dopaminergic aﬀerents express the majority
of transporters and channels similar to the soma, thus it was
assumed that an enhanced dopamine release might contribute
to the described MPP+ eﬀects. In addition, dopamine D1/D5-
and D2-like receptors are expressed on pre- and post-synaptic
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FIGURE 5 | MPP+ alters mIPSC frequency. (A) Sample traces of mIPSCs
before and after vehicle application are shown for the indicated time points. HC
values are indicated in pA. (B) Whole-cell voltage-clamp recordings are
presented for the time points before (baseline), and after 10 and 30 min MPP+
wash-in. The diagrams depict the cumulative fractions of mIPSC (C) amplitudes
and inter-event intervals (D) for an individual experiment before (baseline) and
following 10 and 30 min of MPP+ wash-in. (E) Bar graph summarizes
normalized mIPSC amplitudes recorded in experiments with and with-out
(control) MPP+ application. Data are presented for the 10- and 30-min time
points of vehicle or MPP+ wash-in. mIPSC amplitudes were normalized to the
respective values of before the vehicle or MPP+ application. (F) Bar diagram
summarizes normalized mIPSC frequencies. (G) The bar graph shows the
values of HC normalized to their HC baseline values (first 3 min). In graph (F,G)
the range of the significant difference between control and MPP+ per time point
is indicated with brackets and asterisks (p < 0.05; Mann–Whitney test).
Asterisks in a circle indicate a significant difference of the 10 and 30 min values
to their own baseline values before drug application (Wilcoxon paired
signed-ranks test).
compartments of hippocampal excitatory neurons (Goldsmith
and Joyce, 1994). In contrast to this assumption we did not notice
signiﬁcant eﬀects of D1/D5- and D2-like receptor antagonists on
MPP+ mediated fEPSP depression. Only the initial enhancement
of the fEPSPs was antagonized by blocking D2-like dopamine
receptors using the antagonist haloperidol, but not by sulpiride.
Since haloperidol is known to antagonize other receptors, such
as sigma, 5-HT2 and muscarinic receptors, it might be prudent
to suggest that D2-like receptors are not involved in MPP+
mediate eﬀects on fEPSPs. In addition, co-application of D2-like
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FIGURE 6 | Effects of GABAA and GABAB receptor antagonists on
MPP+-mediated fEPSP depression. (A) Application of the GABAA
receptor antagonist bicuculline (Bic 10 µM, light gray filled triangles)
30 min before MPP+ 100 µM application up to the end of the recording
significantly reduced the fEPSP-slope depression significantly in
comparison to MPP+ 100 µM application only (black circles). Bicuculline
did not alter the fEPSP’s baseline stability. (B) Application of the GABAB
receptor antagonist CGP52432 (CGP) prolonged the MPP+ mediated
fEPSP enhancement but did not alter the degree of fEPSP depression.
Baseline fEPSP sample traces and traces for the 15- and 60-min time
points are shown above the graphs. The horizontal scale bar indicates
10 ms and the vertical one 0.5 mV. The application period of MPP+ or
GABA receptor antagonists is shown with black or gray horizontal lines,
respectively. Brackets enclose the time points with a significant difference
between groups (∗p < 0.05). The compared groups are indicated with
their corresponding symbols above the brackets.
and D1/D5-like dopamine receptor antagonists did not alter the
dynamic of fEPSP modulation by 100 µMMPP+.
Since the present experiments indicated that the hippocampal
dopaminergic system is not required in the MPP+ induced
fEPSP modulation we analyzed whether MPP+ causes
alteration of the hippocampal inhibitory system. The GABAergic
system is involved in regulation of synaptic transmission by
activation of GABAergic autoreceptors localized on presynaptic
compartments of inhibitory and excitatory neurons (Ault
and Nadler, 1982; Davies and Collingridge, 1996). These
autoreceptors have been shown to regulate the homeostatic
activity of the GABAergic system by feedback inhibition
(Axmacher and Draguhn, 2004) and are able to induce post-
synaptic shunt eﬀects (Draguhn et al., 2008) by retardation and
suppression of the presynaptic vesicle release in excitatory nerve
terminals. The down regulation of excitatory vesicle release has
been shown for the GABAB receptor agonist baclofen, which
activates autoreceptors to enhance feed-forward inhibition and
reduces synaptic transmission in CA1 neurons (Davies and
Collingridge, 1996). In addition, a study of Ault and Nadler
(1982) indicated that 20 µM (±) baclofen can reduce the fEPSP
to 20 ± 7% of baseline in the hippocampus SC-CA1 pathway,
a level of fEPSP depression similar to our observation. Baclofen
is also known for its presynaptic eﬀects in CA1 neurons, for
reducing the mEPSC frequency without modulation of mEPSC
amplitude. This eﬀect is thought to be mediated by direct
binding of baclofen to GABAB receptors and consequently does
not alter mIPSC frequency and amplitude (Scanziani et al.,
1992).
One way to analyze the strength of the inhibitory circuits
in the hippocampus is based on the appearances of polyspikes
in response to repeated stimulations and loss of inhibition
(Saghatelyan et al., 2004). We found that MPP+ attenuates the
appearance of polyspikes, which indicates that MPP+ enhances
some aspects of the GABAergic system. In a further eﬀort to
characterize the eﬀects of MPP+ on the GABAergic system the
amplitude and frequency of mIPSCs were studied. Here MPP+
increased the mIPSC frequency without signiﬁcant alteration of
their amplitude. Application of a GABAB receptor antagonist did
not prevent MPP+ mediated fEPSP depression, but increased the
MPP+ induced fEPSP enhancement. Thus, the involvement of
autoreceptors, mainly mediated by GABAB receptor activation,
seems not to be responsible for the MPP+ induced fEPSP
depression.
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However, our experiments with MPP+ indicated an alteration
of the GABAergic system by other mechanisms, because
MPP+ enhanced mIPSC frequency and the MPP+ induced
fEPSP depression was only attenuated by a GABAA receptor
antagonist. That enhanced activity of GABAA receptors is
able to alter neuronal activity was shown, for instance, for
ethanol, which increases tonic inhibition through activation
of GABAA receptors, leading to a reduction of fEPSPs in
the DG region (Wei et al., 2004). In addition, an increased
extracellular GABA concentration was found to enhance tonic
inhibition of neuronal circuits with an overall impact on the
excitatory activity of neurons (Caraiscos et al., 2004). One of the
diﬀerences between GABAB and GABAA receptors is that they
are prone to desensitization, which might contribute to the low
impact of GABAB receptors in tonic inhibition (Kanaide et al.,
2007). In addition, the GABAA receptors that are involved in
tonic inhibition are based on a diﬀerent subunit composition
and therefore distinguishable from GABAA receptors that are
participating in phasic inhibition. The GABAA receptors that
mediate tonic inhibition require alpha5 subunits and respond
to low, ambient GABA concentration and have an extrasynaptic
localization (Caraiscos et al., 2004). The involvement of these
alpha5 subunits containing GABAA receptors in a learning
task was indicated by an enhanced memory performance of
alpha5-null mutant mice (Collinson et al., 2002; Martin et al.,
2010) and by memory impairments due to an increase in
alpha5 GABAA receptor function (Zurek et al., 2014). In
addition, ethanol induced impairments in discriminative tasks
rely on alpha5 subunit containing GABAA receptors (Platt et al.,
2005).
In contrast to the mechanisms of the MPP+ induced fEPSP
depression, the initial fEPSP increase by MPP+ seems to be
not mediated by GABAA receptor activation, because bicuculline
does not alter the initial phase. GABAB receptor blockage
increased the initial phase, thus there might be some complicated
interaction of MPP+ within the diﬀerent components of the
GABAergic system. It requires supplementary experiments to
decipher these putative interactions.
Conclusion
Bringing these data together, we suggest that MPP+ aﬀects
hippocampal synaptic transmission by modulating the
hippocampal GABAergic system causing thereby an alteration
of the eﬃciency of excitatory synaptic transmission. Whether
MPP+ aﬀects GABAA receptors directly or activates them by
an increase of the ambient GABA concentrations remains to be
investigated.
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